South Korea's GL Rapha will make more than 150 million doses of Sputnik V coronavirus vaccine per year, Russia's sovereign wealth fund said on Friday, one of its biggest production deals announced so far as Moscow aims to boost output abroad. While Russia is ramping up its domestic production capacities, which will be focused on meeting its own needs, it has also reached agreements to produce 500 million doses annually abroad, which will supply other countries. The South Korean deal marks a second production agreement since Russia said on Wednesday that the vaccine was found to be 92% effective at protecting people from COVID-19 according to interim trial results.